PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding-Reference-Cited by-同舟云学术

PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding

Author:

Wang M.¹^ORCID,Lawrence J. B.²,Quon D. V.³,Ducore J.⁴,Simpson M. L.⁵,Boggio L. N.⁵,Mitchell I. S.⁶^ORCID,Yuan G.²,Alexander W. A.⁷,Schved J.-F.⁸

Affiliation:

1. Hemophilia and Thrombosis Center; University of Colorado; Aurora CO USA

2. LFB USA Inc.; Framingham MA USA

3. Orthopaedic Hemophilia Treatment Center; Orthopaedic Institute for Children; Los Angeles CA USA

4. University of California, Davis; Comprehensive Cancer Center; Hematology/Oncology Clinic; Sacramento CA USA

5. Rush University Medical Center; Chicago IL USA

6. GLOVAL; LLC; Broomfield CO USA

7. HEMA Biologics; LLC; Louisville KY USA

8. Département d'Hématologie Biologique; Hôpital Saint-Eloi; CHU Montpellier; Montpellier France

Funder

LFB SA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

Reference41 articles.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

5. Pain relief with Eptacog beta in haemophilia patients with inhibitors;GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark;2023-02